Effect of Graves' disease and methimazole on warfarin anticoagulation

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1200-1203

  Busenbark, Laura A ^a   Cushnie, Sally A ^b,c  

^a University of Florida ^*  (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Fort Myers VA Outpatient Clinic   (United States)

Author keywords

Atrial fibrillation; Hyperthyroidism; Hypothyroidism; Methimazole; Warfarin

Indexed keywords

DEXAMETHASONE; DILTIAZEM; ENOXAPARIN; LIOTHYRONINE; METOPROLOL; SIMVASTATIN; THIAMAZOLE; THYROTROPIN; THYROXINE; VITAMIN K GROUP; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; DRUG MEGADOSE; DRUG MONITORING; GRAVES DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERNATIONAL NORMALIZED RATIO; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOEMBOLISM; THYROID FUNCTION TEST; VITAMIN INTAKE;

ANTICOAGULANTS; ANTITHYROID AGENTS; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; THYROID FUNCTION TESTS; THYROID HORMONES; WARFARIN;

EID: 33745114427     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G422     Document Type: Article

References (13)

1. Package insert. Coumadin (warfarin sodium). Princeton, NJ: Bristol-Myers Squibb, June 2002.
2. Stephens MA, Self TH, Lancaster D, Nash T. Hypothyroidism: effect on warfarin anticoagulation. South Med J 1989;82:1585-6.
3. Package insert. Tapazole (methimazole). Bristol, TN: King Pharmaceuticals, February 2004.
4. Ross DS. The medical management of Graves disease. Endoc Pract 1995;1:193-9.
5. Forfar JC, Caldwell GC. Hyperthyroid heart disease. Clin Endocrinol Metab 1985;14:491-508.
6. Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid 2002;12:489-93.
7. Staffurth JS, Gibberd MC, Ng Tang, Fui S. Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 1977;2:688-90.
8. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:429-56. DOI 10.1378/chest 126.3_suppl.429S
9. Vagenakis AG, Cote R, Miller ME, Braverman LE, Stohlman F. Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis. Johns Hopkins Med J 1972;131:69-73.
10. McIntosh TJ, Brunk SF, Kolln I, Fouts JR, Wilson WR. Increased sensitivity to warfarin in thyrotoxicosis (abstract). J Clin Invest 1970;49:63a.
11. Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986;58:43-51.
12. Hansten PD. Drug interactions update. Oral anticoagulants and drugs which alter thyroid function. Drug Intell Clin Pharm 1980;14:331-4.
13. Chute JP, Ryan CP, Sladek G, Mohamed Sakir KM. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism. Endocr Pract 1997;3:77-9.